MARKET WIREReuters • 3h ago
Russia's FSB says minor detained over park attack threat after US tip-off - ReutersRussia's FSB says minor detained over park attack threat after US tip-off Reuters
Why SCTX Stock slipped -0.57% Today — RQD Quant Desk Flash
$17.44 -0.57% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)
EXT / AFTER-HRS: $17.39
Scribe Therapeutics Inc. (SCTX) carries a Roarable Rating of D (Sell) with 50/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
ROARABLE D • SELL / AVOID
Cap $330.2M
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER
Click Any Pre-Computed AI Quant Specialist Briefing on SCTX Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief)
Is SCTX stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼
As of 2026-11-01, Scribe Therapeutics Inc. (NASDAQ: SCTX) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 50/100 at a spot price of $17.44 (-0.57% 1D, market cap $330.2M). Pillar breakdown: Fundamental Cash Engine 10/20, Institutional 13F & Options Flow 8/20, Executive Insider Alignment 13/20, FRED Macro Regime Fit 10/20, and SEC Balance-Sheet Forensics 9/20. Across 1016 tracked Health Care issuers, SCTX ranks #345 in composite RQD confidence.
✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief)
How does SCTX compare to ALEC and XFOR in the Health Care sector?
▼
Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), SCTX carries a Roarable D (50/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, ALEC (Alector Inc.) holds a E grade (32/100 RQD, P/E N/A, ROIC -35.0%, cap $332.1M) and XFOR (X4 Pharmaceuticals Inc.) posts a D- grade (35/100 RQD, P/E N/A, ROIC -35.0%, cap $333.1M). Among the 5-stock peer group, SCTX leads on earnings multiple (N/A) while ALEC leads on capital efficiency (-35.0% ROIC).
✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief)
What are the biggest fundamental strengths and SEC risk factors for SCTX?
▼
Per SCTX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001853921), Scribe Therapeutics Inc. generated $0 in revenue, $0 in net income, and $0 in free cash flow against $78.2M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
EXT / AFTER-HRS: $17.39 (-0.29%)🧬 Disciplined Float (-0.40% YoY Shares)⚙️ Cash Engine: 10/20 (D) • 0.2% FCF Margin
Verify 90D Bucket Audit →📊 Historical Track Record: Scores of 50/100 (D) historically posted market-perform odds over rolling 90-day windows (-1.4% avg 90D alpha vs SPY • 49.3% hit rate — wait for RQD ≥ 70 breakout).
Audit Bucket Track Record →RQD QUANT TACHOMETERSELL / AVOID • D
2-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
5-PILLAR SNOWFLAKE RADARRw D · Rk D+
Each axis scored 0–20
12M PRICE TARGET CONE-3.6% Base Target
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for SCTX)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (50/100 Composite)
🔍 WHY SCTX SCORES 50/100 (D) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+13/20 pts (26% of score)
Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 7/9
▲ #2 Bullish Driver: Cash Engine Quality+10/20 pts (20% of score)
SEC XBRL FY 2025 (10-K): 0.2% FCF Margin ($9.2M FCF) & 52% Gross Margin
▼ #1 Drag / Risk Factor: Whale & Options Positioning8/20 pts (-12 pt drag)
Put hedging (50% put share) caps near-term gamma upside (-12 pts vs max)
📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)Grade C$21.17-5.1% Next Q
58
Q2 (-2Q)Grade C$20.08-23.3% Next Q
55
Q3 (-1Q)Grade C-$15.41+13.2% Next Q
53
CurrentGrade D$17.44-1.4% Hist 90D α
50
Trajectory: C (58) → D (50)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER
⚔️ Adversarial Opposing Case: What Could Spark a SCTX Turnaround Squeeze
While SCTX currently carries a cautious 50/100 (D) rating due to Whale & Options Positioning (8/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
🚀 Contrarian Squeeze Trigger #1
Established market leader in Health Care with deep daily trading liquidity.
🚀 Contrarian Squeeze Trigger #2
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($24.10) and Max Pain ($18.31) forces dealer call-delta covering toward $41.58.
🚀 Contrarian Squeeze Trigger #3
Forensic Repair Trigger: Halting share dilution (Disciplined Float (-0.40% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
🎲 LIVE PREDICTION MARKET ODDS TIED TO $SCTX• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “SCTX Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →
Why SCTX Stock slipped -0.57% Today — RQD Quant Desk Flash
Scribe Therapeutics Inc. (SCTX) slipped -0.57% to $17.44, trading at 15% of its 52-week range ($13.5 – $39.6). Stretched risk/reward at current multiples (steady margins) under elevated 10-year interest-rate pressure.
- ▸Technical Tape: Trading at 15% of its 52-week range ($13.5 – $39.6) with RSI-14 at 36.8 (NEUTRAL RANGE).
- ▸Volatility Profile: Historical 20-day realized swing band of ±12.5% around $17.44 (no active unusual options sweep snapshot on file).
- ▸Fundamental Anchor: Roarable D (Sell) backed by 52% gross margin and $9.2M annual free cash flow.
Live SCTX Headlines & Catalysts
MARKET WIREReuters • 3h ago
Oil slips more than 1% as talks continue on ending Iran war - ReutersOil slips more than 1% as talks continue on ending Iran war Reuters
MARKET WIREReuters • 4h ago
Nine people dead in Learjet crash in south Florida, officials say - ReutersNine people dead in Learjet crash in south Florida, officials say Reuters
MARKET WIREReuters • 6h ago
Iran's IRGC Navy says two tankers 'exploded' after hitting mines in Hormuz - ReutersIran's IRGC Navy says two tankers 'exploded' after hitting mines in Hormuz Reuters
MARKET WIRECNBC • 8h ago
Here are 3 big things we're watching in the stock market in the week aheadThe market could use a few victories in the days ahead, which will be filled with more earnings, an election, and jobs data.
MARKET WIRECNBC • 8h ago
Democratic Rep. Stevens endorses Rogers over El-Sayed in Michigan Senate electionHaley Stevens had lost the Democratic nomination for Senate in Michigan to Abdul El-Sayed earlier this year.
RISK WATCHReuters • 10h ago
Israeli strikes kill eight people in Gaza - medics say - ReutersIsraeli strikes kill eight people in Gaza - medics say Reuters
MARKET WIREReuters • 11h ago
Iran, Qatari mediators hold third day of talks to end US-Iran war - ReutersIran, Qatari mediators hold third day of talks to end US-Iran war Reuters
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk
Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring SCTX)
- ✓Walkthrough of SCTX's RQD Radar, SEC cash-conversion gap & downside invalidation levels
- ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
- ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
SCTX // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -8.07%▼ DESCENDING CHANNEL
2026-10-30O $17.00H $17.44L $14.77C $17.44VOL 479.2K
RES: $29.10SUP: $2.65SMA50: $24.10SMA200: $23.81
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK
SCTX Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Share Count & Dilution Monitor (#25)
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
Reverse-DCF Expectations Hurdle (#30)
8.0%/yr Implied 5Y Growth
vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
Ellis Vennor Setup Ledger (#33)
No active Ellis Vennor swing setup published on SCTX today. View full Setup Ledger →
🦋 Documented & Second-Order Butterfly Connections
Open Graph →
No direct multi-tier Butterfly edges indexed yet for SCTX. Explore sector supply chains on /butterfly.
AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for SCTX today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK
📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (SCTX)
Health Care Rank #345 of 1016
⚔️ ALEC vs SCTX Full Matrix →
1. Head-to-Head Health Care Peer Comparison (SCTX vs. ALEC, XFOR, AGEN, IRLA)
Industry: Biotechnology: Biological Products (No Diagnostic Substances) (156 Tracked Issuers)Across 1016 tracked Health Care securities in the Roarable RQD universe, Scribe Therapeutics Inc. (SCTX) ranks #345 by composite RQD confidence (50/100, grade D) and #509 by equity capitalization ($330.2M). Within this direct 5-issuer industry benchmark cohort, SCTX leads on earnings valuation at N/A trailing P/E, while ALEC leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. SCTX currently leads its immediate peer cohort in composite quantitative strength at 50/100 (D).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| SCTX
ACTIVE
Scribe Therapeutics Inc. | D | 50/100 | — | — | — | -0.57% | $330.2M | Benchmark Subject |
| ALEC Alector Inc. | E | 32/100 | — | — | -35.0% | -0.44% | $332.1M | /alec-vs-sctx → |
| XFOR X4 Pharmaceuticals Inc. | D- | 35/100 | — | 83.6% | -35.0% | +0.30% | $333.1M | /xfor-vs-sctx → |
| AGEN Agenus Inc. | E | 26/100 | — | 96.0% | -35.0% | -0.56% | $320.2M | /agen-vs-sctx → |
| IRLA IRulya Therapeutics Inc. | E | 32/100 | — | — | -35.0% | -4.05% | $342.8M | /irla-vs-sctx → |
2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2025–FY2025)
SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001853921In its most recent audited fiscal period (FY2025, filed 2025-12-31), Scribe Therapeutics Inc. (SCTX) reported GAAP revenue of $0 , GAAP net income of $0, operating cash flow of $0, and free cash flow of $0 . On the balance sheet, SCTX closed FY2025 with $78.2M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: N/A).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $0 | $0 | — | — | $78.2M | — |
3. SCTX Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)
✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLEDIs SCTX stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
As of 2026-11-01, Scribe Therapeutics Inc. (NASDAQ: SCTX) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 50/100 at a spot price of $17.44 (-0.57% 1D, market cap $330.2M). Pillar breakdown: Fundamental Cash Engine 10/20, Institutional 13F & Options Flow 8/20, Executive Insider Alignment 13/20, FRED Macro Regime Fit 10/20, and SEC Balance-Sheet Forensics 9/20. Across 1016 tracked Health Care issuers, SCTX ranks #345 in composite RQD confidence.
How does SCTX compare to ALEC and XFOR in the Health Care sector?
Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), SCTX carries a Roarable D (50/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, ALEC (Alector Inc.) holds a E grade (32/100 RQD, P/E N/A, ROIC -35.0%, cap $332.1M) and XFOR (X4 Pharmaceuticals Inc.) posts a D- grade (35/100 RQD, P/E N/A, ROIC -35.0%, cap $333.1M). Among the 5-stock peer group, SCTX leads on earnings multiple (N/A) while ALEC leads on capital efficiency (-35.0% ROIC).
What are the biggest fundamental strengths and SEC risk factors for SCTX?
Per SCTX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001853921), Scribe Therapeutics Inc. generated $0 in revenue, $0 in net income, and $0 in free cash flow against $78.2M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
Where is SCTX trading relative to its 50-day, 200-day, and 52-week technical levels?
SCTX last traded at $17.44 (-0.57% on volume of 252,928 shares), positioning the stock -27.63% below its 50-day simple moving average ($24.10) and -26.75% below its 200-day simple moving average ($23.81). Across its 52-week range of $13.50 to $39.60, SCTX sits at the 15.1% percentile with a 14-day RSI of 36.8 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($15.26 to $19.62).
SCTX Investor FAQ & Complete 8-Part Research Index
100% OPEN ACCESS • SEC EDGAR × CBOE × FREDWhy is SCTX stock moving today?
Why SCTX Stock slipped -0.57% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (steady margins) under elevated 10-year interest-rate pressure.